Catalyst Biosciences Inc (NASDAQ:CBIO) – Equities researchers at B. Riley upped their Q3 2018 EPS estimates for shares of Catalyst Biosciences in a note issued to investors on Thursday, June 21st. B. Riley analyst G. Zavoico now expects that the biopharmaceutical company will post earnings per share of ($0.59) for the quarter, up from their prior forecast of ($0.68). B. Riley currently has a “Neutral” rating and a $12.50 target price on the stock. B. Riley also issued estimates for Catalyst Biosciences’ Q4 2018 earnings at ($0.61) EPS, FY2018 earnings at ($2.36) EPS, Q1 2019 earnings at ($0.65) EPS, Q2 2019 earnings at ($0.69) EPS, Q3 2019 earnings at ($0.72) EPS, Q4 2019 earnings at ($0.85) EPS, FY2019 earnings at ($2.91) EPS, FY2020 earnings at ($3.82) EPS, FY2021 earnings at ($4.87) EPS and FY2022 earnings at ($2.74) EPS.
Several other research analysts have also recently issued reports on CBIO. BidaskClub raised shares of Catalyst Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, June 19th. ValuEngine raised shares of Catalyst Biosciences from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $35.00 target price on shares of Catalyst Biosciences in a report on Tuesday, June 19th. Finally, Zacks Investment Research raised shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a report on Tuesday, May 15th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $25.83.
Shares of Catalyst Biosciences stock opened at $10.52 on Monday. Catalyst Biosciences has a 52-week low of $3.11 and a 52-week high of $37.00.
Catalyst Biosciences (NASDAQ:CBIO) last issued its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.59. Catalyst Biosciences had a negative net margin of 2,983.40% and a negative return on equity of 39.27%. The company had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.23 million.
Institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN raised its holdings in Catalyst Biosciences by 148.3% in the first quarter. Wells Fargo & Company MN now owns 8,940 shares of the biopharmaceutical company’s stock worth $231,000 after buying an additional 5,340 shares during the last quarter. Spark Investment Management LLC purchased a new position in Catalyst Biosciences in the first quarter worth about $330,000. Ardsley Advisory Partners purchased a new position in Catalyst Biosciences in the fourth quarter worth about $205,000. Tibra Equities Europe Ltd purchased a new position in Catalyst Biosciences in the first quarter worth about $587,000. Finally, EAM Global Investors LLC purchased a new position in Catalyst Biosciences in the first quarter worth about $644,000. 76.76% of the stock is owned by institutional investors and hedge funds.
Catalyst Biosciences Company Profile
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.